Hearing Sets Stage for Stem Cell Funding Debate

Just prior to offering the floor to Harold Varmus for the first Labor, Health and Human Services, and Education subcommittee hearing in more than two months, and just after exchanging pleasantries with the National Institutes of Health director, subcommittee chairman Sen. Arlen Specter (R-Pa.) asked Varmus jokingly, "Did you like the $2 billion we gave you?" A smiling Varmus answered in the affirmative; onlookers chuckled. "It's my belief that stem cells do not fall under the ban on embryo re

Written byEugene Russo
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Just prior to offering the floor to Harold Varmus for the first Labor, Health and Human Services, and Education subcommittee hearing in more than two months, and just after exchanging pleasantries with the National Institutes of Health director, subcommittee chairman Sen. Arlen Specter (R-Pa.) asked Varmus jokingly, "Did you like the $2 billion we gave you?" A smiling Varmus answered in the affirmative; onlookers chuckled.

"It's my belief that stem cells do not fall under the ban on embryo research."--Sen. Tom Harkin As of now, however, none of that recent $2 billion NIH funding increase (to a total budget of $15.64 billion) can be put toward research that involves the creation of human embryos for research purposes--so dictates the president's 1994 directive. But if the tone of the Dec. 2 hearing on the ethical and scientific implications of stem cells is any indication of what's to come, NIH scientists may ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies